Wed, Aug 21, 2024
Strong growth in Divi's Lab. What’s Driving the Boom?
More >
Mon, May 27, 2024
Dividend Stocks List 2024: Companies are announcing their quarterly results and with this, many of them are also declaring dividends for investors. On Saturday, around 10 companies declared dividends.
Wed, Apr 03, 2024
At close, shares of Divi's Laboratories traded 1.65 per cent or Rs 59.65 higher, at Rs 3,681 apiece on the BSE. The market capitalisation of the company at around the same time stood at Rs 97,718.98 crore.
Mon, Feb 06, 2023
Top Gainers and Losers: Meanwhile, a mixed trend on the sectoral front and selective buying on the broader front kept the participants busy.
Wed, Nov 09, 2022
The shareholding in the company crossed the 5 per cent mark on November 7, 2022. The acquisition of shares was done at an average price of Rs 3,379.01, LIC said in a regulatory filing.
Mon, Nov 07, 2022
Except for Nifty Pharma, almost all sectoral indices closed positive. Nifty Metal followed by banking and financials contributed most to the market surge during today’s session.
Divis lab share price: The stock was at its 52-week low at Rs 3488.80 per share. On both the indices between 12:52 pm to 12:55 pm from around Rs 3,600 apiece and to Rs 3,400 apiece.
Tue, Nov 01, 2022
Sectorally, Nifty Metal and Pharma aided the market most to gain, up over 2 per cent, similarly, Nifty IT and Realty too surged between 1-2 per cent at the close.
Tue, May 24, 2022
The stock on Tuesday slipped almost 6.5 per cent to touch a new 52-week low of Rs 3650 per share on Tuesday. It breached its earlier low of Rs 3,790 touched on January 24, 2022.
Mon, May 23, 2022
As per the regulatory filing of Divi’s Lab, the consolidated profit grew by over 78 per cent to Rs 894.6 crore in Q4FY22 as compared to Rs 502 crore in the same quarter a year ago.
Fri, Feb 11, 2022
Pharmaceutical major Divi’s Laboratories on Friday reported a robust October-December quarter earnings for the financial year 2021-22 (Q3FY22).
Mon, Nov 08, 2021
Pharmaceutical major Divi's Laboratories shares tumbled around 9 per cent to Rs 4,751 per share on the BSE intraday trade on Monday on the back of weak operational performance in the second quarter of the financial year 2021-22 (Q2FY21).
Wed, Oct 27, 2021
In the 20-share index, 17 advanced while 3 declined. The 52-week high is 14,938.25. The biggest gainers were Divi’s Laboratories Limited followed by Sun Pharmaceuticals Industries Limited and Strides Pharma Limited which were up almost 2.9, 2.1 and 2.1 per cent respectively
Tue, Oct 05, 2021
Indian market snapped 4-day losing streak and closed in the green on Monday. The S&P BSE Sensex rallied by more than 500 points while the Nifty50 closed above 17600.
Mon, Oct 04, 2021
The index heavyweight — Divi’s Laboratories shares spurted 10 per cent to hit a new all-time high of Rs 5,313.80 per share on the BSE intraday trade on Monday. The stock mainly jumped after the US-based pharma giant Merck & Co’s announcement of positive results of their antiviral pill trail.
Mon, May 31, 2021
For the year 2021, Divi's Laboratories has earned consolidated total revenue of Rs 7032 cr for the financial year 2020-21 as against Rs 5584 cr during the previous year, reflecting a growth of 26%. PBT for the current year grew by 47% to 2666 cr as against a PBT of Rs 1819 cr for the previous year. PAT for the year amounted to Rs 1984 cr as against a PAT of Rs 1377 cr for the last year, reflecting a growth of 44%
Mon, May 10, 2021
Divi’s Laboratories has a solid base in the industry, Divi's Laboratories is extending its product offerings in the generic API segment, developing 16 additional APIs to lead the next phase of growth and the subsequent DMF filing. Divi’s Laboratories has more than doubled its capacity and is poised to take advantage of carotenoids' growing market
Thu, Apr 08, 2021
Divi’s Laboratories share price closed at Rs 3708, up Rs 9 or 0.25%. Divi’s Laboratories share price moved from Rs 3610 to Rs 3708 in one week. Ashis Biswas, Head of Technical Research at CapitalVia Global Research says that technically Divi’s Labs looks good for a target of Rs 3980
Fri, Apr 02, 2021
Ashis Biswas, Head of Technical Research at CapitalVia Global Research highlights Fundamentals and Technical Analysis on Divi’s Laboratories. The target price on Divi’s Lab is Rs 3770. In addition to having a solid base in the industry, Divi's Laboratories is extending its product offerings in the generic API segment, developing 16 additional APIs to lead the next phase of growth and the subsequent DMF filing
Wed, Mar 24, 2021
Divi's Laboratories is expected to benefit from strong growth likely in the global active pharmaceutical ingredients (API) space, driven by multiple factors. Increasing preference for biologics for disease management, key drugs going off patent, outsourcing opportunities and higher regulatory approvals would be key growth drivers for the API industry, which is expected to report a high single-digit CAGR over the next 6-7 years.
Mon, Mar 22, 2021
Established in 1990, Divi’s Laboratories is engaged in the manufacture of generic APIs and intermediates, custom synthesis of active ingredients and advanced intermediates for pharma MNCs, other speciality chemicals like Carotenoids and complex compounds.
Mon, Feb 08, 2021
Divi’s Laboratories reported in-line Q3 FY21 earnings. This was led by healthy traction in Generics / Custom Synthesis (CS), coupled with lower raw material cost, driven by process improvements. Meaningful benefit is yet to accrue from the major capex phase. 10 new molecules under development in generic APIs and contrast media APIs would provide a fillip going forward.
Mon, Dec 07, 2020
Divi's Laboratories is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) in the world. Growth prospects of Divi’s look decent with favorable traits in the API industry due to supply chain readjustments/ diversification from China into other countries including India amid the COVID-19 pandemic. As global players are looking to reduce dependency on China and preferring India, companies like Divi’s remain well placed to capitalize on such opportunities. Also, in custom synthesis, the company is connected with several pharma giants and looks to benefit as India may tap opportunities in terms of the consumption of custom synthesis.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
